 SAN DIEGO, Oct. 29, 2020 GLOBE NEWSWIRE -- Kura Oncology, Inc. Nasdaq: KURA, a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open of U.S. financial markets on Thursday, November 5, 2020. Kuras management will host a webcast and conference call at 8 a.m. ET 5 a.m. PT that day to discuss the financial results and provide a corporate update. 